Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large b-cell lymphoma of the bone (the IELSG-14 study).
Authors
Bruno VFerreri, A
Gospodarowicz, M
Govi, S
Messina, C
Porter, D
Radford, John A
Heo, D
Park, Y
Martinelli, G
Taylor, E
Lucraft, H
Hong, A
Scarfò, L
Zucca, E
Christie, D
Affiliation
Unit of Lymphoid Malignancies, Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, ItalyIssue Date
2014
Metadata
Show full item recordAbstract
The clinical features, management, and prognosis of stage I-II diffuse large B-cell lymphoma of the bone (PB-DLBCL) included in an international database of 499 lymphoma patients with skeletal involvement were reviewed. Methods. HIV-negative patients (n = 161) with diffuse large B-cell lymphoma of the bone (PB-DLBCL) after complete staging workup were considered. The primary objective of this study was to identify the most effective treatment modality; the secondary objectives were to define the contribution of irradiation fields and doses and the pattern of relapse. Results. Median age was 55 years (range, 18-99 years), with a male/female ratio of 1:2; 141 (87%) patients had stage I, 14 (9%) had B symptoms, 37 (23%) had bulky lesion, 54 (33%) showed elevated lactate dehydrogenase serum levels, and 25 (15%) had fracture. Thirteen (8%) patients received chemotherapy alone, 23 (14%) received radiotherapy alone, and 125 (78%) received both treatments. The response to the first-line treatment was complete in 131 of 152 assessed patients (complete response rate, 86%; 95% confidence interval [CI], 81%-91%) and partial in 7, with an overall response rate of 91% (95% CI, 87%-95%). At a median follow-up of 54 months (range, 3-218), 107 (67%) patients remained relapse-free, with a 5-year progression-free survival of 68% (SE: 4). Four (2.5%) patients had meningeal relapse; 119 patients were alive (113 disease-free), with a 5-year overall survival of 75% (SE: 4). Patients managed with primary chemotherapy, whether followed by radiotherapy or not, had a significantly better outcome than patients treated with primary radiotherapy, whether followed by chemotherapy or not. The addition of consolidative radiotherapy after primary chemotherapy was not associated with improved outcome; doses >36 Gy and the irradiation of the whole affected bone were not associated with better outcome. Conclusion. Patients with PB-DLBCL exhibit a favorable prognosis when treated with primary anthracycline-based chemotherapy whether followed by radiotherapy or not. In patients treated with chemoradiotherapy, the use of larger radiation fields and doses is not associated with better outcome. Central nervous system dissemination is a rare event in PB-DLBCL patients.Citation
Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study). 2014, 19 (3):291-298 OncologistJournal
The OncologistDOI
10.1634/theoncologist.2013-0249PubMed ID
24567283Type
ArticleLanguage
enISSN
1549-490Xae974a485f413a2113503eed53cd6c53
10.1634/theoncologist.2013-0249
Scopus Count
Collections
Related articles
- Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study).
- Authors: Messina C, Ferreri AJ, Govi S, Bruno-Ventre M, Gracia Medina EA, Porter D, Radford J, Heo DS, Park HY, Pro B, Jayamohan J, Visco C, Scarfò L, Zucca E, Gospodarowicz M, Christie D, International Extranodal Lymphoma Study Group (I.E.L.S.G.)
- Issue date: 2014 Mar
- The clinical features, management and prognostic effects of pathological fractures in a multicenter series of 373 patients with diffuse large B-cell lymphoma of the bone.
- Authors: Govi S, Christie D, Messina C, Bruno Ventre M, Gracia Medina EA, Porter D, Radford J, Seog Heo D, Park Y, Martinelli G, Taylor E, Lucraft H, Ballova V, Zucca E, Gospodarowicz M, Ferreri AJ, International Extranodal Lymphoma Study Group (I.E.L.S.G.)
- Issue date: 2014 Jan
- Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.
- Authors: Tao R, Allen PK, Rodriguez A, Shihadeh F, Pinnix CC, Arzu I, Reed VK, Oki Y, Westin JR, Fayad LE, Medeiros LJ, Dabaja B
- Issue date: 2015 May 1
- [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
- Authors: Zou GR, Zhang YJ, Xie FY, Zheng W, Li HX, Xia YF, Lin TY, Lu TX
- Issue date: 2006 Dec
- New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
- Authors: Cai QQ, Hu LY, Geng QR, Chen J, Lu ZH, Rao HL, Liu Q, Jiang WQ, Huang HQ, Lin TY, Xia ZJ
- Issue date: 2016 Sep 13